RKLB (Rocket Lab) is a superior space investment compared to SPCE (Virgin Galactic), and the author is holding through the SPCX (SpaceX's upcoming SPAC listing). Key risks include execution delays, competition from SpaceX, and market volatility in the space sector.

Trade SpaceX IPO catalysts by shorting ASTS puts during allocation days (June 8-10) expecting fund selling pressure, then reversing to buy ASTS/RKLB LEAPs around June 22 when SpaceX enters Nasdaq 100, which should trigger a broad space stock rally. Key risks: SpaceX IPO timing uncertain, IV crush on options, index inclusion timing unpredictable, forced liquidation may not materialize.

Argument that Rocket Companies (RKT) could benefit from retail investor mania similar to SPCX and RKLB, exploiting the fact that retail traders may buy stocks with 'rocket' in the name without analyzing fundamentals. The thesis relies on momentum and speculation rather than solid financial analysis.

Author anticipates a SpaceX IPO-driven rally in space stocks similar to past IPO runs (Coinbase, Rivian), targeting SPCE (Virgin Galactic) as a potential 400x trade due to recent resumption of operations announcement, heavy short interest, and upcoming catalysts including Q4 2024 space flights. Key risks include speculative nature, execution delays (company has history of delays), IPO timing uncertainty, and potential "buy the rumor, sell the news" dynamic.

Rocket Lab (RKLB) is positioned as a compelling value play in the commercial space launch sector, trading at ~$4-5B market cap with 100+ successful satellite launches and 20+ proven orbital missions, significantly lower valuation than SpaceX ($90B) and Virgin Galactic ($10B) while planning expansion into larger Neutron rockets for human spaceflight. Key risks include execution on Neutron development, competition from SpaceX's dominance, and the speculative nature of space industry valuations.